The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones

J Med Chem. 1996 Feb 2;39(3):665-8. doi: 10.1021/jm950395a.

T M Willson ¹, J E Cobb, D J Cowan, R W Wiethe, I D Correa, S R Prakash, K D Beck, L B Moore, S A Kliewer, J M Lehmann

Affiliations

Affiliation

1 Glaxo Wellcome Research and Development, Research Triangle Park, North Carolina 27709, USA.

PMID: 8576907 DOI: 10.1021/jm950395a

Products

Cat. No.

Product Name

Description

Target

Research Area
HY-17386

Rosiglitazone

99.94%, PPARγ Agonist

PPAR; TRP Channel; Autophagy; Ferroptosis; Apoptosis

Neurological Disease; Metabolic Disease; Inflammation/Immunology; Cancer
HY-14600

Rosiglitazone maleate

99.88%, PPARγ Activator

PPAR; TRP Channel; Autophagy; Ferroptosis

Metabolic Disease; Inflammation/Immunology; Cancer
HY-17386A

Rosiglitazone hydrochloride

99.31%, PPARγ Agonist

PPAR; TRP Channel; Autophagy; Ferroptosis; Apoptosis

Neurological Disease; Metabolic Disease; Inflammation/Immunology; Cancer
HY-W011220

Ciglitazone

98.89%, PPARγ Agonist

PPAR

Cardiovascular Disease; Cancer
HY-17386B

Rosiglitazone potassium

PPARγ Agonist

PPAR; TRP Channel; Autophagy; Apoptosis; Ferroptosis

Neurological Disease; Metabolic Disease; Inflammation/Immunology; Cancer
HY-17386S

Rosiglitazone-d₃

Stable Isotope

Isotope-Labeled Compounds; PPAR; TRP Channel; Autophagy; Ferroptosis

Neurological Disease; Metabolic Disease; Inflammation/Immunology; Cancer
HY-14600R

Rosiglitazone maleate (Standard)

PPARγ Activator

PPAR; TRP Channel; Autophagy; Ferroptosis

Metabolic Disease; Inflammation/Immunology; Cancer
HY-17386S1

Rosiglitazone-d₄

Stable Isotope

Ferroptosis; Autophagy; TRP Channel; PPAR; Apoptosis; Isotope-Labeled Compounds

Neurological Disease; Metabolic Disease; Inflammation/Immunology; Cancer
HY-17386R

Rosiglitazone (Standard)

PPARγ Agonist

PPAR; TRP Channel; Autophagy; Ferroptosis; Apoptosis

Neurological Disease; Metabolic Disease; Inflammation/Immunology; Cancer

Name
Email *

	Sorry, but the email address you supplied was invalid.